Posts Tagged: PITX2

Webinar: A clinical view on PITX2 DNA methylation in high-risk breast cancer

A webinar program for oncologists and pathologists Thursday, Feb. 22, 2018 at 1:00 p.m. CET Anthracycline-based chemotherapy is the recommended standard-of-care for certain high-risk breast cancer patients including lymph node-positive, estrogen receptor-positive and HER2-negative high-risk breast cancer patients. However, not all patients benefit equally from this chemotherapy. Learn more about a novel, validated marker that… Read article →


PITX2: A novel biomarker to support breast cancer therapy selection

PITX2 DNA methylation status is a clinically relevant biomarker to predict survival in a variety of cancers, including breast cancer, and is a predictive biomarker for treatment response in high- risk breast cancer patients. Applying PITX2 methylation as a predictive biomarker can help avoid use of chemotherapy in patients that would receiveĀ  little or no… Read article →